However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...

Aide to RFK Jr. says White House is pushing for global price parity on GLP-1 drugs for weight loss. Read more here.

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

In this article, we will take a look at the 12 Major Stocks to Buy According to Billionaires. The U.S. stock market had one of the worst starts, at least the worst start to a presidency since 1928.

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO.

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

US President Donald Trump signed an executive order requiring drugmakers to lower prices, aligning with international rates.